A Phase 3 interventional study of Sitagliptin and Glipizide in Diabetes Mellitus, Type 2 and Renal Insufficiency, Chronic, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2017-05-12.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 42nd largest by enrollment of the 197 interventional ones that give a count, is one of 17 that started in 2007, is one of 74 in phase 3, and was the 30th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 30 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 17 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 426 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 56th largest by enrollment of the 170 interventional ones that give a count, is one of 19 that started in 2007, is one of 86 in phase 3, and was the 27th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to compare how sitagliptin and glipizide lower blood glucose levels in participants with moderate or severe renal insufficiency.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Sitagliptin + Placebo for Glipizide
Drug: Sitagliptin · Drug: Placebo for Glipizide
Glipizide + Placebo for Sitagliptin
Drug: Glipizide · Drug: Placebo for Sitagliptin
Participants with moderate renal insufficiency will receive two sitagliptin 25 mg tablets orally daily; participants with severe renal insufficiency will receive one sitagliptin 25 mg tablet orally daily
Also known as: MK-0431, Januvia
Participants will receive glipizide 2.5 mg (1/2 tablet) orally once daily up to 20 mg orally daily (10 mg twice daily)
Also known as: Glucotrol
Participants with moderate renal insufficiency will receive 2 placebo for sitagliptin tablets orally daily; participants with severe renal insufficiency will receive 1 placebo for sitagliptin tablet orally daily
Participants will receive 1/2 tablet of placebo for glipizide orally once daily up to 2 tablets orally twice daily
Change From Baseline in Hemoglobin A1c (A1C) Levels at Week 54
A1C represents percentage of glycosylated hemoglobin.
Time frame: Baseline to Week 54
Percentage of Participants With Hypoglycemic Events
Percentage of participants with at least one symptomatic hypoglycemic adverse event, excluding data after initiation of glycemic rescue therapy.
Time frame: Baseline up to 28 days following the last dose of study therapy
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 54
Time frame: Baseline to Week 54
Change From Baseline in Body Weight at Week 54
Time frame: Baseline to Week 54
| Milestone | Sitagliptin | Glipizide |
|---|---|---|
| Started | 211 | 212 |
| Completed | 164 | 170 |
| Not completed | 47 | 42 |
| Withdrew: Adverse event | 16 | 18 |
| Withdrew: Other | 2 | 2 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 6 |
| Withdrew: Physician decision | 1 | 3 |
| Withdrew: Protocol violation | 2 | 2 |
| Withdrew: Withdrawal by subject | 24 | 11 |
A1C represents percentage of glycosylated hemoglobin.
| Percent of glycosylated hemoglobin | Sitagliptin | Glipizide |
|---|---|---|
| Baseline | 7.76 ± 0.65 | 7.79 ± 0.70 |
| Change from Baseline at Week 54 | -0.70 ± 0.80 | -0.62 ± 0.91 |
Percentage of participants with at least one symptomatic hypoglycemic adverse event, excluding data after initiation of glycemic rescue therapy.
| percentage of participants | Sitagliptin | Glipizide |
|---|---|---|
| Percentage of Participants With Hypoglycemic Events | 6.2 | 17.0 |
| mg/dL | Sitagliptin | Glipizide |
|---|---|---|
| Baseline | 148.6 ± 39.9 | 143.9 ± 35.7 |
| Change from Baseline at Week 54 | -16.7 ± 47.1 | -20.2 ± 48.6 |
| kg | Sitagliptin | Glipizide |
|---|---|---|
| Change From Baseline in Body Weight at Week 54 | -0.6 ± 0.3 | 1.2 ± 0.3 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin | — | 36/210 (17.1%) | 69/210 (32.9%) |
| Glipizide | — | 38/212 (17.9%) | 89/212 (42%) |
| Event | Sitagliptin | Glipizide |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 1/210 | 4/212 |
| Urinary tract infectionInfections and infestations | 3/210 | 1/212 |
| Cardiac failure congestiveCardiac disorders | 0/210 | 3/212 |
| Myocardial infarctionCardiac disorders | 2/210 | 1/212 |
| Cerebrovascular accidentNervous system disorders | 2/210 | 1/212 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 2/210 | 0/212 |
| Acute myocardial infarctionCardiac disorders | 1/210 | 2/212 |
| Cardiac failureCardiac disorders | 0/210 | 2/212 |
| Renal failure acuteRenal and urinary disorders | 1/210 | 2/212 |
| Renal failure chronicRenal and urinary disorders | 1/210 | 2/212 |
| Event | Sitagliptin | Glipizide |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 12/210 | 35/212 |
| Blood glucose decreasedInvestigations | 15/210 | 32/212 |
| Urinary tract infectionInfections and infestations | 11/210 | 20/212 |
| Oedema peripheralGeneral disorders | 15/210 | 10/212 |
| Upper respiratory tract infectionInfections and infestations | 10/210 | 15/212 |
| DiarrhoeaGastrointestinal disorders | 11/210 | 12/212 |
| HypertensionVascular disorders | 11/210 | 6/212 |
| DizzinessNervous system disorders | 7/210 | 11/212 |
| Age, Continuous(years) | Sitagliptin | Glipizide | Total |
|---|---|---|---|
| Mean | 64.2 ± 10.7 | 64.2 ± 9.4 | 64.2 ± 10.1 |
| Sex: Female, Male(Participants) | Sitagliptin | Glipizide | Total |
|---|---|---|---|
| Female | 80 | 90 | 170 |
| Male | 131 | 122 | 253 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
Ran from Oct 2007 to primary completion in Mar 2011, 41 months.
Results were first posted in Mar 2012, 1 year after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 41 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sitagliptin